• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.BRCA1 或 BRCA2 相关癌症并非不可避免的证据。
Mol Med. 2012 Dec 6;18(1):1327-37. doi: 10.2119/molmed.2012.00280.
2
Chromosomal mutagen sensitivity associated with mutations in BRCA genes.与BRCA基因突变相关的染色体诱变敏感性。
Cytogenet Genome Res. 2004;104(1-4):325-32. doi: 10.1159/000077511.
3
Increased rates of spontaneous sister chromatid exchange in lymphocytes of BRCA2+/- carriers of familial breast cancer clusters.家族性乳腺癌聚集性BRCA2+/-携带者淋巴细胞中姐妹染色单体自发交换率增加。
Cancer Lett. 2004 Jul 8;210(1):85-94. doi: 10.1016/j.canlet.2004.01.014.
4
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.BRCA1和BRCA2突变携带者的淋巴细胞放射敏感性及其对乳腺癌易感性的影响。
Int J Cancer. 2007 Oct 1;121(7):1631-6. doi: 10.1002/ijc.22915.
5
Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2.在含有BRCA1或BRCA2种系突变的人类细胞中存在单倍型不足的证据。
Int J Cancer. 2002 Feb 10;97(5):557-61. doi: 10.1002/ijc.10109.
6
Therapeutic exploitation of tumor cell defects in homologous recombination.同源重组中肿瘤细胞缺陷的治疗性利用。
Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267.
7
BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.BRCA1和BRCA2可防止在DNA复制过程中转化为双链断裂的氧化性DNA损伤。
DNA Repair (Amst). 2015 Jun;30:11-20. doi: 10.1016/j.dnarep.2015.03.002. Epub 2015 Mar 17.
8
BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.BRCA1在DNA损伤应答中调节RAD51功能,并抑制自发的姐妹染色单体复制滑移:对姐妹染色单体黏连、基因组稳定性和致癌作用的影响。
Cancer Res. 2005 Dec 15;65(24):11384-91. doi: 10.1158/0008-5472.CAN-05-2156.
9
Male BRCA mutation carriers: clinical characteristics and cancer spectrum.男性 BRCA 基因突变携带者:临床特征和癌症谱。
BMC Cancer. 2018 Feb 13;18(1):179. doi: 10.1186/s12885-018-4098-y.
10
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.BRCA1和BRCA2通路与乳腺癌或卵巢癌以外的其他癌症风险
MedGenMed. 2005 Jun 29;7(2):60.

引用本文的文献

1
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.从免疫角度探索 BRCA1 和 BRCA2 种系突变相关的乳腺癌和卵巢癌。
BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
2
Comment on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'.对“携带BRCA1和BRCA2突变女性的白血病发病率:一项国际前瞻性队列研究”的评论
Br J Cancer. 2016 Aug 23;115(5):e2. doi: 10.1038/bjc.2016.192. Epub 2016 Jul 26.
3
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.通过离子激流DNA测序经常检测到人类乳腺癌肿瘤中的PIK3CA和TP53基因突变。
PLoS One. 2014 Jun 11;9(6):e99306. doi: 10.1371/journal.pone.0099306. eCollection 2014.
4
Mutations in components of antiviral or microbial defense as a basis for breast cancer.抗病毒或微生物防御成分的突变是乳腺癌的基础。
Funct Integr Genomics. 2013 Nov;13(4):411-24. doi: 10.1007/s10142-013-0336-1. Epub 2013 Sep 21.

本文引用的文献

1
Multiple genotoxic activities of ptaquiloside in human lymphocytes: aneugenesis, clastogenesis and induction of sister chromatid exchange.百脉根苷在人淋巴细胞中的多种遗传毒性活性:变导性、断裂剂和姐妹染色单体交换的诱导。
Mutat Res. 2012 Aug 30;747(1):77-81. doi: 10.1016/j.mrgentox.2012.04.010. Epub 2012 Apr 28.
2
Oxidatively generated complex DNA damage: tandem and clustered lesions.氧化生成的复杂 DNA 损伤:串联和聚集损伤。
Cancer Lett. 2012 Dec 31;327(1-2):5-15. doi: 10.1016/j.canlet.2012.04.005. Epub 2012 Apr 25.
3
Sister chromatid exchanges in breast cancer patients who underwent chemotherapy.乳腺癌患者化疗后姐妹染色单体交换。
J Toxicol Sci. 2012;37(2):235-43. doi: 10.2131/jts.37.235.
4
Clonal architecture of secondary acute myeloid leukemia.继发性急性髓系白血病的克隆结构。
N Engl J Med. 2012 Mar 22;366(12):1090-8. doi: 10.1056/NEJMoa1106968. Epub 2012 Mar 14.
5
Epigenomics and chromatin dynamics.表观基因组学与染色质动力学。
Genome Biol. 2012 Feb 24;13(2):313. doi: 10.1186/gb-2012-13-2-313.
6
Sister chromatid exchange assessment by chromosome orientation-fluorescence in situ hybridization on the bovine sex chromosomes and autosomes 16 and 26.通过染色体定向荧光原位杂交技术对牛性染色体以及常染色体16和26进行姐妹染色单体交换评估。
Cytogenet Genome Res. 2012;136(2):107-16. doi: 10.1159/000335749. Epub 2012 Jan 26.
7
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.非家族性 BRCA1 和 BRCA2 突变携带者的乳腺癌风险:来自乳腺癌家族登记处的研究结果。
J Clin Oncol. 2011 Dec 1;29(34):4505-9. doi: 10.1200/JCO.2010.34.4440. Epub 2011 Oct 31.
8
Human BRCA1-associated breast cancer: no increase in numerical chromosomal instability compared to sporadic tumors.人类BRCA1相关乳腺癌:与散发性肿瘤相比,染色体数目不稳定性未增加。
Cytogenet Genome Res. 2011;135(2):84-92. doi: 10.1159/000332005. Epub 2011 Oct 24.
9
Mutagenic and morphologic impacts of 1.8GHz radiofrequency radiation on human peripheral blood lymphocytes (hPBLs) and possible protective role of pre-treatment with Ginkgo biloba (EGb 761).1.8GHz 射频辐射对人外周血淋巴细胞(hPBL)的致突变性和形态影响及银杏叶提取物(EGb 761)预处理的可能保护作用。
Sci Total Environ. 2011 Dec 1;410-411:59-64. doi: 10.1016/j.scitotenv.2011.09.036. Epub 2011 Oct 19.
10
p53 null fluorescent yellow direct repeat (FYDR) mice have normal levels of homologous recombination.p53 缺失荧光黄色直接重复(FYDR)小鼠具有正常水平的同源重组。
DNA Repair (Amst). 2011 Dec 10;10(12):1294-9. doi: 10.1016/j.dnarep.2011.09.009. Epub 2011 Oct 12.

BRCA1 或 BRCA2 相关癌症并非不可避免的证据。

Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.

机构信息

Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois Chicago, Chicago, Illinois 60607, USA.

出版信息

Mol Med. 2012 Dec 6;18(1):1327-37. doi: 10.2119/molmed.2012.00280.

DOI:10.2119/molmed.2012.00280
PMID:22972572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3521784/
Abstract

Inheriting a BRCA1 or BRCA2 gene mutation can cause a deficiency in repairing complex DNA damage. This step leads to genomic instability and probably contributes to an inherited predisposition to breast and ovarian cancer. Complex DNA damage has been viewed as an integral part of DNA replication before cell division. It causes temporary replication blocks, replication fork collapse, chromosome breaks and sister chromatid exchanges (SCEs). Chemical modification of DNA may also occur spontaneously as a byproduct of normal processes. Pathways containing BRCA1 and BRCA2 gene products are essential to repair spontaneous complex DNA damage or to carry out SCEs if repair is not possible. This scenario creates a theoretical limit that effectively means there are spontaneous BRCA1/2-associated cancers that cannot be prevented or delayed. However, much evidence for high rates of spontaneous DNA mutation is based on measuring SCEs by using bromodeoxyuridine (BrdU). Here we find that the routine use of BrdU has probably led to overestimating spontaneous DNA damage and SCEs because BrdU is itself a mutagen. Evidence based on spontaneous chromosome abnormalities and epidemiologic data indicates strong effects from exogenous mutagens and does not support the inevitability of cancer in all BRCA1/2 mutation carriers. We therefore remove a theoretical argument that has limited efforts to develop chemoprevention strategies to delay or prevent cancers in BRCA1/2 mutation carriers.

摘要

BRCA1 或 BRCA2 基因突变可导致复杂 DNA 损伤修复缺陷。这一步导致基因组不稳定,可能导致乳腺癌和卵巢癌的遗传易感性。复杂 DNA 损伤被视为细胞分裂前 DNA 复制的一个组成部分。它会导致暂时的复制阻滞、复制叉崩溃、染色体断裂和姐妹染色单体交换(SCEs)。DNA 的化学修饰也可能作为正常过程的副产物自发发生。含有 BRCA1 和 BRCA2 基因产物的途径对于修复自发的复杂 DNA 损伤或在无法修复时进行 SCE 是必不可少的。这种情况造成了一种理论上的限制,即实际上存在无法预防或延迟的自发 BRCA1/2 相关癌症。然而,大量关于高自发 DNA 突变率的证据是基于使用溴脱氧尿苷(BrdU)测量 SCE 得出的。在这里,我们发现 BrdU 的常规使用可能导致对自发 DNA 损伤和 SCE 的高估,因为 BrdU 本身就是一种诱变剂。基于自发染色体异常和流行病学数据的证据表明外源性诱变剂有强烈的影响,并且不支持所有 BRCA1/2 突变携带者中癌症的必然性。因此,我们消除了一个理论上的论点,该论点限制了开发化学预防策略以延迟或预防 BRCA1/2 突变携带者癌症的努力。